Recombinant adeno-associated viral (rAAV) vectors have been used in over 200 clinical trials with a good safety profile and significant clinical benefit in a number of genetic diseases. Moreover, because of their ability to infect non-dividing and dividing cells and to act as an efficient substrate for homologous recombination, rAAVs are being used as a tool for gene-editing approaches.